AlloVir develops allogeneic, virus-specific T cell (VST) therapy candidates targeting 11 different viruses for treatment or prevention.

AlloVir

AlloVir, formerly ViraCyte, was founded in 2013 and is the leader in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The company’s technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T cells targeting devastating viral pathogens for immunocompromised patients under viral attack. AlloVir’s technology and manufacturing process enables the potential for the treatment and/or prevention of up to six devastating viruses with each single allogeneic cell therapy. The company is advancing multiple mid- and late-stage clinical trials across its product portfolio.

Cancer Prevention and Research Institute of Texas

Redmile Group

EcoR1 Capital

ElevateBio

F2 Ventures

Gilead Sciences

GMT Capital

Invus

Kite Pharma

Samsara BioCapital

Leerink Partners

Fidelity Management and Research Company

Today AlloVir announced that it will stop three ongoing Phase 3 trials of its lead multi-virus-specific T cell therapy, posoleucel, for futility. Learn more here: https://lnkd.in/eZ7NWu3A

Posoleucel is an investigational #Tcell therapy designed to target six common viruses that can have devastating consequences for people with immune deficiency. 

This T cell therapy is a living investigational drug, comprised of both CD8+ and CD4+ virus-specific T cells which expand in the presence of viral antigens, selectively killing the virus-infected cells, then contract once the virus is no longer detected.

Explore the science: https://lnkd.in/ebf_JHNM

#viraldisease #biotechnology #virology #innovation

Earlier this week our team gathered to celebrate the upcoming holiday season and reflect on our accomplishments in 2023. We are excited for the progress we have made this year with our lead investigational therapy, posoleucel.
#ExCELLenceAtAlloVir #celebration #biotechnology #culture

In case you missed it, AlloVir's CEO, Diana Brainard, participated in a fireside chat during the @PiperSandler 35th Annual Healthcare Conference. To learn more about AlloVir and our VST platform, listen here: https://lnkd.in/euE4njdu

#biotechnology #celltherapy #investmentbanking

November is the time of year when we take a moment to pause and reflect on all we are grateful for in our lives.  This year, we asked our colleagues at AlloVir to let us know what they are thankful for.  See some of their responses below! #ExCELLenceAtAlloVir #biotechnology #employeeengagement

Join our CEO, Diana Brainard, MD, for a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday November 28th, at 10AM ET.

Learn more here: https://lnkd.in/euE4njdu

#biotechnology #investmentbanking

Our CEO, Diana Brainard, MD, sat down with biotech reporter Luke Timmerman for his podcast, “The Long Run with Luke Timmerman” to discuss her background and the impact virus-specific T cells could have on infectious diseases.

Listen to the episode here: https://lnkd.in/efuEmT9Q

On Veteran's Day, we would like to take a moment to recognize the brave individuals who have helped protect our country and keep us safe at home and abroad. 

Thank you for your service. #veteransday

More than 80% of allo-HCT patients reactivate one or more viruses and with limited to no treatment options when patients do reactivate a virus, there is a high unmet need within this population. 

Our investigational T cell therapy, posoleucel, seeks to treat or prevent six common but devastating viruses: adenovirus (AdV), BK virus (BKV), cytomegalovirus (CMV), Epstein-Barr virus, (EBV), human herpesvirus (HHV-6), and JC virus (JCV).

Posoleucel has the potential to transform care for transplant recipients.
#celltherapy #innovation #biotechnology

Join Francesca Cardarelli, MD, FAST, AlloVir’s Senior Director of Clinical Development, on Saturday, November 4th at American Society of Nephrology's #KidneyWk.

Dr. Cardarelli will present data from AlloVir's Phase 2 trial of our multi-virus specific #tcell therapy, posoleucel, in kidney transplant patients with BK viremia. #clinicaltrials

COM:ALLOVIR

AlloVir

Financials Not Available